Celularity Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Celularity Inc. (CELU) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $10.38 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-04-30
- Celularity Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-12-31 was $3.25M.
- Celularity Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $2.04M, a 23.62% decline year-over-year.
- Celularity Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $2.45M, a 18.13% decline year-over-year.
- Celularity Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-03-31 was $2.64M, a 11.09% decline year-over-year.
- Celularity Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $10.38M, a 10.29% decline from fiscal 2024.
- Celularity Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $11.57M, a 22.96% decline from fiscal 2023.
- Celularity Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $15.02M, a 5.29% decline from fiscal 2022.
- Celularity Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $15.86M, a 60.37% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2025-12-31 | $3.25M derived: 10-K 12 month − 3 quarters · filed 2026-04-30 | $5.29M derived: sum of 2 quarters · filed 2026-04-30 | $7.74M derived: sum of 3 quarters · filed 2026-04-30 | $10.38M 10-K · filed 2026-04-30 |
| 2025-09-30 | $2.04M 10-Q · filed 2025-11-14 | $4.49M derived: sum of 2 quarters · filed 2025-11-14 | $7.13M derived: sum of 3 quarters · filed 2025-11-14 | |
| 2025-06-30 | $2.45M 10-Q · filed 2025-11-14 | $5.08M derived: sum of 2 quarters · filed 2025-11-14 | ||
| 2025-03-31 | $2.64M 10-Q · filed 2025-11-14 | |||
| 2024-12-31 | $11.57M 10-K · filed 2026-04-30 | |||
| 2024-09-30 | $2.67M 10-Q · filed 2025-11-14 | $5.66M derived: sum of 2 quarters · filed 2025-11-14 | $8.63M derived: sum of 3 quarters · filed 2025-11-14 | |
| 2024-06-30 | $2.99M 10-Q · filed 2025-11-14 | $5.96M derived: sum of 2 quarters · filed 2025-11-14 | ||
| 2024-03-31 | $2.97M 10-Q · filed 2025-11-14 | |||
| 2023-12-31 | $15.02M 10-K · filed 2025-05-08 | |||
| 2023-09-30 | $3.60M 10-Q · filed 2024-12-06 | $7.45M derived: sum of 2 quarters · filed 2024-12-06 | $11.44M derived: sum of 3 quarters · filed 2024-12-06 | |
| 2023-06-30 | $3.86M 10-Q · filed 2024-12-06 | $7.84M derived: sum of 2 quarters · filed 2024-12-06 | ||
| 2023-03-31 | $3.99M 10-Q · filed 2024-12-06 | |||
| 2022-12-31 | $15.86M 10-K · filed 2024-07-30 | |||
| 2022-09-30 | $4.52M 10-Q · filed 2024-01-03 | $9.05M derived: sum of 2 quarters · filed 2024-01-03 | $11.47M derived: sum of 3 quarters · filed 2024-01-03 | |
| 2022-06-30 | $4.53M 10-Q · filed 2024-01-03 | $6.95M derived: sum of 2 quarters · filed 2024-01-03 | ||
| 2022-03-31 | $2.42M 10-Q · filed 2024-01-03 | |||
| 2021-12-31 | $40.01M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $8.88M 10-Q · filed 2022-11-10 | $37.07M derived: sum of 2 quarters · filed 2022-11-10 | $38.08M derived: sum of 3 quarters · filed 2022-11-10 | |
| 2021-06-30 | $28.19M 10-Q · filed 2022-11-10 | $29.20M derived: sum of 2 quarters · filed 2022-11-10 | ||
| 2021-03-31 | $1.01M 10-Q · filed 2022-11-10 | |||
| 2020-12-31 | $4.37M 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $1.08M 10-Q · filed 2021-11-12 | $2.53M derived: sum of 2 quarters · filed 2021-11-12 | $3.35M derived: sum of 3 quarters · filed 2021-11-12 | |
| 2020-06-30 | $1.44M 10-Q · filed 2021-11-12 | $2.27M derived: sum of 2 quarters · filed 2021-11-12 | ||
| 2020-03-31 | $828.00K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |